resencatinib

Resencatinib is an investigational **oral small-molecule selective RET kinase inhibitor** being developed by Hansoh Pharmaceutical for RET-altered solid tumors, with the most advanced public development in **RET fusion-positive locally advanced or metastatic non-small cell lung cancer**. Publicly cited phase 1/2 data identify resencatinib as the nonproprietary name for **HS-10365**, a potent and selective inhibitor of RET signaling designed to suppress oncogenic RET fusions and related RET-driven tumor growth. The available sources describe capsule-based oral administration, including a phase 1/2 study in advanced solid tumors and a dedicated pharmacokinetic study in subjects with hepatic impairment.

Other names

resencatinib